Augmented Probability of Thromboembolic Events versus High Bleeding Risk Associated with COVID-19

The SARS-CoV-2 virus infection carries a higher risk of thromboembolic complications as well as a greater propensity for bleeding. We reviewed the relevant PubMed articles discussing the prevalence, category of patients, the moment of occurrence, and evolution of venous thromboembolism (VTE), but also of venous and arterial “in situ” thrombosis (AT), and hemorrhagic events as well and identified 58 significant scientific papers, including 10 meta- analyses and 19 cohort studies. Depending on the population under study, most experts concur that there is an increased prevalence of thromboembolic events, which can range from 25 to 31% for VTE. Lower incidence of AT and hemorrhagic complications between 4.8 and 8%, or roughly 2-3%, respectively were recorded. These events predominantly affected elderly patients with moderate- to severe-stage COVID-19 and other comorbidities. It's vital to note that individuals who experienced hemorrhages usually used anticoagulant medications for thromboprophylaxis. The evolution of patients infected with the SARS-CoV-2 virus is exacerbated as a result of thromboembolic and hemorrhagic consequences, both of which are significant negative prognostic indicators, leading to an increased morbidity and mortality of this population.